Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 9/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856066 | 0.86 | SLC6A9 (0.56) | SLC6A9KMT2AUSP30POLBMEN1 | |
| SCHEMBL13098086 | 0.80 | SLC6A9 (0.45) | SLC6A9HPGDKMT2AUSP30ANO1 | |
| SCHEMBL3059626 | 0.79 | SLC6A9 (0.60) | SLC6A9HPGDKMT2AMEN1 | |
| SCHEMBL3055700 | 0.78 | SLC6A9 (0.59) | SLC6A9HPGDKMT2AMEN1 | |
| SCHEMBL7803787 | 0.77 | SLC6A9 (0.50) | SLC6A9KMT2AMEN1GPR119 | |
| SCHEMBL3894370 | 0.76 | SLC6A9 (0.58) | SLC6A9HPGDKMT2AMEN1 | |
| SCHEMBL2850636 | 0.75 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL7895891 | 0.75 | SLC6A9 (0.62) | SLC6A9HPGDKMT2A | |
| SCHEMBL9948274 | 0.74 | GPR119 (0.50) | ADORA2AADORA2BUSP30POLBGPR119 | |
| SCHEMBL3059786 | 0.73 | SLC6A9 (0.63) | SLC6A9HPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207155-B2 | Sulfonyl-azetidin-3-yl-methylamine amide analogs as GlyTl inhibitors, methods for making same, and use of same in treating psychiatric disorders | VANDERBILT UNIVERSITY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207155-B2 | Sulfonyl-azetidin-3-yl-methylamine amide analogs as GlyTl inhibitors, methods for making same, and use of same in treating psychiatric disorders | VANDERBILT UNIVERSITY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207155-B2 | Sulfonyl-azetidin-3-yl-methylamine amide analogs as GlyTl inhibitors, methods for making same, and use of same in treating psychiatric disorders | VANDERBILT UNIVERSITY (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100261696-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
| US-20100261696-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
| US-20100261696-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
| WO-2010114907-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261696-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | SLC1A2, SLC1A1, SLC18A2 | SLC6A9 23/4885ADORA2A 860/4885ADORA2B 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.